The early stages of research related to drug discovery, including the identification of a relevant target and a viable lead compound, play a crucial role in the overall success of a drug in preclinical and / or clinical studies. The process of drug discovery is extremely demanding, both in terms of capital expenses and time. Moreover, there is always a high risk of failure associated with R&D programs and, given the increasing regulatory stringency, the approval of new drugs has become significantly complex as well. Over the years, outsourcing has emerged as a popular trend in the pharmaceutical and biotechnology industry, and has demonstrated the potential to effectively cater to the growing demands associated with drug discovery as well. Contract Research Organizations (CROs), with dedicated teams of experts and innovative solutions across the various stages of the drug discovery and development process, are now located in all major global markets. Employing the services of these CROs offers a number of benefits to drug developers, including access to better technologies, latest R&D tools, cost and time savings and the potential to minimize risks associated with the drug discovery process.
Specifically, the oncology market, with an estimated global prevalence of 32 million, imposes a heavy burden on the healthcare system. There exists a significantly high unmet need for novel therapeutic options in this domain, translating into a growing demand for drug discovery initiatives. Therefore, CROs have now emerged as important stakeholders in the oncology market. The increasing trend towards outsourcing has triggered the establishment of several strategic collaborations between drug / therapy developers and CROs. In fact, several CROs have acquired other small / mid-sized CROs or collaborated with them for upgrading their own drug discovery capabilities in an effort to provide integrated services to its clients. Opportunities arising from the growth of personalized medicines, the vast unmet need for therapies for orphan indications, and the adoption of novel technology solutions, such as deep learning solutions, cloud-based technology platforms and 3D cell culture systems, are likely to act as some of the primary drivers of growth within this sector.
SCOPE OF THE REPORT
The “Oncology Drug Discovery Services Market, 2017-2030” report features an extensive study of the current market landscape and the future potential of CROs providing drug discovery services in oncology. Cancer, one of the leading causes of death worldwide, is an extremely complex disease and medical science is still struggling to figure out the various factors associated with the disease’s origin, propagation, spread (metastasis) and relapse. In fact, in 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer.
With the increasing complexity of drug discovery and development process, the overall spending on R&D in the pharmaceutical / biotechnology sector has increased over the past few years. According to one particular source, this spending has increased from USD 108 billion in 2006 to USD 145 billion in 2016. Heavy investments are being made towards the discovery of novel approaches for the treatment of various types of cancers. The industry is currently under tremendous pressure not only to meet the expectations of a growing patient population but also to identify ways to address the risks associated with novel drug discovery programs. Over the years, CROs offering drug discovery services have contributed significantly and have now grown to become an integral and indispensable part of the pharmaceutical and biotechnology industry.
This study presents an in-depth analysis of a diverse set of companies that offer services across the different steps, such as target identification, target validation, hit generation, hit-to-lead and lead optimization, of the drug discovery process. In addition to other elements, the report features:
A discussion on the current state of the market with respect to key players, along with information on the location of headquarters, drug discovery services provided (target identification, target validation, hit generation, hit-to-lead, lead optimization), depth of service portfolio (discovery / preclinical / clinical / commercial manufacturing) and product type (biologics / small molecules).
Elaborate profiles of established / emerging players. Each profile features a company overview, financial information, drug discovery service portfolio, recent developments and a view on its future outlook and strategy.
An overview of the most active regions in terms of drug discovery services for oncology. The report contains schematic representations of world maps that clearly indicate the location of drug discovery hubs across the world.
A comprehensive benchmark analysis, comparing the existing capabilities of various stakeholders within their respective peer groups, to identify ways to become more competitive in the industry. The analysis is based on key parameters such as the depth of service portfolio, the type of molecules researched and the nature of services offered by different companies.
An analysis of the agreements that have been established in the recent past, covering drug discovery agreements / research collaborations, license agreements, acquisitions, service alliances and joint venture agreements.
A competitive landscape review, featuring a multivariate bubble analysis, based on parameters such as the geographical location, founding year, number of drug discovery services offered and the level of partnering activity in recent years.
A discussion on the potential growth areas such as personalized medicines, orphan drugs and complex biopharmaceuticals, and innovative technologies including deep learning solutions and 3D cell culture systems, that are likely to present opportunities or act as growth drivers during the coming years.
In addition, the study features a detailed analysis of the existing market size and the future growth potential of the oncology drug discovery services market for the period 2017-2030. We have provided insights on the likely regional evolution of the market, across North America, Europe, China and the rest of the world. Additionally, we have provided informed estimates of the likely market evolution on the basis of type of product (small molecule, biologics) and key steps of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization). In order to account for the uncertainties associated with some of the key parameters, and to add robustness to our model, we have presented three different forecast scenarios, depicting the conservative, base and optimistic tracks of the market’s evolution.
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of this study, we invited over 100 stakeholders to participate in a survey, in order to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field.
1. During our research, we identified over 115 companies that are actively involved in providing a wide array of oncology drug discovery services; hit-to-lead and lead optimization are amongst the most common services offered by these CROs.
2. Around 25% of the companies offer end-to-end services for drug discovery, starting from target identification till lead optimization. Examples of such one stop shops include (in alphabetical order) Charles River Laboratories, Evotec, GE Healthcare Life Sciences, GenScript, Lonza, PerkinElmer, Syngene, and TCG Lifesciences.
3. The current market is characterized by the presence of several established, as well as emerging CROs. Examples of established players with more than 25 years of overall experience in pharmaceutical sector include AMRI, Aurora Fine Chemicals, Cayman Chemical, ChemDiv, Dalton Pharma Services, DavosPharma, Organix, SRI Biosciences and Syncom. Some of the new players that have recently entered this domain include (in alphabetical order) Abzena, Aurelia Bioscience, Envigo, Enzymlogic, HitGen, INOVOTION, New England Discovery Partners and Tybema BioSolutions.
4. Over 80% of these CROs are located in Europe and North America. It is also worth highlighting that there are several players offering CRO services for oncology drug discovery in certain emerging regions within Asia Pacific, namely India and China. Examples of some of the large-sized CROs based in these locations include (in alphabetical order) Aurigene, GVK Biosciences, Pharmaron, Piramal Pharma Solutions, Sai Life Sciences, ChemPartner and WuXi AppTec.
5. Although the services offered by these companies range from early drug discovery to drug development and commercialization, there are several companies that solely focus on providing drug discovery services. These include (in alphabetical order) Aquila BioMedical, Aris Pharmaceuticals, Attana, Axxam, Beactica, BellBrook Labs, BioDiscovery Group, CanAm Bioresearch, CreaGen Biosciences, Domainex, Evotec, Exiris, Icagen, Organix, Sapient Discovery, Viva Biotech and Zobio.
6. The market has witnessed significant partnering activity in the past three years; several CROs have forged strategic alliances with other services providers in order to expand their drug discovery capabilities. We identified over 70 such collaborations, inked specifically for oncology research. Over 30% of the agreements signed by CROs with other players, including drug / therapy developers or academic players, were focused on co-conducting research for the discovery of either therapeutic targets or lead molecules. Such agreements also involved several big pharma giants, such as (in alphabetical order) AbbVie, AstraZeneca, Daiichi Sankyo, Debiopharm Group, MERCK and Sanofi. Recent examples of acquisitions that we came across include Villapharma’s acquisition by Eurofins (January 2017), HD Biosciences’ acquisition by Wuxi AppTec (January 2017), Cyprotex’s acquisition by Evotec (December 2016) and Blue Stream Laboratories’ acquisition by Charles River Laboratories (June 2016).
7. Driven by the rising demand for novel therapeutic targets and drugs, and the growing importance of contract services, we expect the market to continue on its growth trajectory in the foreseen future. We expect the oncology drug discovery services market to grow at an annualized rate of 6.2%, over the period 2017-2030. In terms of geography, majority (more than 70%) of the share is distributed between North America and Europe; other countries, such as China, are likely to grow at a relatively faster rate in the coming decade.
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and type of biopharmaceuticals. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market till 2030. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 presents an executive summary of the insights captured in our research. It offers a high level view on the current state of the oncology drug discovery services market, specific factors impacting its growth and how the opportunity is likely to evolve in the mid-long term.
Chapter 3 provides an introduction to the drug discovery approach. It includes details on the time taken for a drug to traverse from the bench to the market, along with a historical account of the evolution of the drug discovery process. It also provides an in-depth explanation of each of the five steps involved in the drug discovery process, including details on associated methods / technologies / approaches. Further, the chapter features a discussion on the key challenges associated with conducting drug discovery research in-house, highlighting the need for contract services providers and the evident shift towards outsourcing drug discovery related operations in oncology.
Chapter 4 includes a comprehensive overview and analysis of the current market landscape of the oncology drug discovery services market. It features an analysis of drug discovery service providers on the basis of their geographical location, type of drug discovery service provided, depth of service portfolio (discovery / preclinical development / clinical development / commercial manufacturing) and the nature of product (small molecule / biologic).
Chapter 5 provides detailed profiles of some of the oncology drug discovery service providers that offer end-to-end services. Each profile features a brief overview of the company, financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.
Chapter 6 provides detailed profiles of some of the oncology drug discovery service providers that offer target based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.
Chapter 7 provides detailed profiles of some of the oncology drug discovery service providers that offer lead based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.
Chapter 8 provides detailed profiles of some of the oncology drug discovery service providers that specialize in lead optimization. Each profile features presents a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.
Chapter 9 provides a comprehensive market forecast, depicting how the drug discovery services market for oncology is likely to evolve till 2030. We have presented an analysis of the evolving financial opportunity across various regions, such as North America, Europe, China and ROW. Additionally, we have analyzed the market size based on the nature of molecule (biologic, small molecule) and the key steps of drug discovery (target identification, target validation, hit-to-lead, lead identification and lead optimization). It is worth mentioning that our projections are backed by credible data procured from both secondary and primary sources, and a robust forecast approach validated by in-house and external experts.
Chapter 10 provides a detailed benchmark analysis of the companies that provide drug discovery services in the oncology domain. The key parameters considered for this analysis include the depth of the service portfolio, the type of the molecule and the number of services offered by each company within a peer group (based on geography and employee base). The analysis allows the companies to compare their existing capabilities within their peer group and identify opportunities to become more competitive in the industry.
Chapter 11 features an elaborate discussion and analysis on the collaborations and partnerships that have been recently inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market. In addition to the aforementioned analysis, the chapter offers an illustrative bubble analysis representing the competitive landscape of players involved in the space, based on their experience, number of drug discovery services offered and the level of activity in terms of collaborations established in the field of oncology research. The key objective of this analysis is to establish a region-wise understanding of contract services offerings and key players involved in the oncology drug discovery market globally.
Chapter 12 highlights important trends that are likely to impact CROs providing drug discovery services and influence their efforts to strengthen their presence in this competitive market. During our research, we identified a number of interesting trends, including focus on personalized medicines, orphan drugs and complex biopharmaceuticals, innovative applications of deep learning, use of 3 D cell culture systems and other novel technologies, which are being developed to reduce the innate complexities associated with drug discovery and optimize the time spent on the overall process. We believe that these trends are likely to significantly influence the industry’s evolution over the coming decade.
Chapter 13 presents insights from the survey conducted for this study. The participants, who were primarily Directors / CXO level representatives, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.
Chapter 14 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and key trends that are likely to determine how the market is likely to evolve in the mid- and long terms.
Chapter 15 is a collection of interview transcripts of the discussions held with some of the key players in this industry.
Chapters 16 is an appendix, which provides tabulated data and numbers for all the figures in the report.
Chapter 17 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.
LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.
3. Academic Medical Center Helsinki
4. Actelion Pharmaceuticals
5. ActivX Biosciences
6. Addex Therapeutics
7. Advinus Therapeutics
8. Agilux Laboratories
9. Agios Pharmaceuticals
10. Albany Molecular Research
13. AnCoreX Therapeutics
14. Anthem Biosciences
15. APEIRON Biologics
17. Aquila BioMedical
18. Aragen Bioscience
19. Aris Pharmaceuticals
21. Asahi Kasei Pharma
22. Asclepia MedChem Solutions
24. Astex Therapeutics
27. Aurelia Bioscience
29. Aurora Fine Chemicals
31. Axon Biochemicals
32. Axon Medchem
34. Babraham Institute
35. Bayer Group
37. BellBrook Labs
38. Beryllium Discovery
42. BioDiscovery Group
44. BioFocus DPI
45. Biomedicum Genomics
47. Bionaturis Group
51. Birkbeck College
52. Blue Stream Laboratories
53. British Columbia Cancer Agency
54. C4X Discovery
55. Cadiz University
56. California Institute for Biomedical Research
57. Caliper Life Sciences
58. CanAm Bioresearch
59. Cancer Research Technology
60. Cancer Research UK
61. Carrick Therapeutics
62. Cayman Chemical
64. Celsis Group
65. Centauri Therapeutics
66. Centro Nacional de Investigaciones Oncológicas
67. Charles River Laboratories
68. Charnwood Molecular
71. ChemoGenics BioPharma
72. Chemveda Life Sciences
73. Child Health and Development Institute of Connection
76. Confluence Discovery Technologies
78. CreaGen Biosciences
81. Curadev Pharma
84. Dabur Group
85. Dabur Research Foundation
86. Daiichi Sankyo
87. Dalton Pharma Services
88. Dana-Farber Cancer Institute
90. Debiopharm Group
93. Dong-A ST
94. Dr. Reddy’s Laboratories
95. École Polytechnique Fédérale de Lausanne
102. Eurofins Scientific
105. Exquiron Biotech
107. Fannin Innovation Studio
108. Felicitex Therapeutics
109. FORMA Therapeutics
110. Free University of Amsterdam
111. Fusion Antibodies
114. Galectin Therapeutics
115. GE Healthcare Life Sciences
117. Genomics Medicine Ireland
119. GL Chemtec International
121. Griffith University
122. GVK Biosciences
123. H3 Biomedicine
124. Harlan Laboratories
125. HD Biosciences
126. Helmholtz Association
128. Horizon Discovery
129. HQL Pharmaceuticals
130. Huntingdon Life Sciences
133. Infinity Pharmaceuticals
136. Insilico Medicine
137. Institut du cancer de Montréal
138. Institute for Research in Immunology and Cancer Commercialization of Research
139. Institute of Cancer Research, London
140. INTEGREX Research
142. IOTA Pharmaceuticals
143. Ipca Laboratories
144. Jagiellonian University
145. Janssen Biotech
146. Janssen Pharmaceuticals
147. Jinan Nornoon Biological Engineering
148. Johnson & Johnson
149. Joseph Fourier University
150. JPT Peptide Technologies
151. Jubilant Biosys
152. Jubilant Life Sciences
153. Juniper Pharma Services
154. Juno Therapeutics
155. KYORIN Pharmaceutical
157. Lead Discovery Center
158. Leiden University
159. Longthera Pharmaceuticals
161. Marshall University
162. Mascot Industries
163. Max Planck Innovation
164. Max Planck Institute of Biochemistry
167. Memorial Sloan Kettering Cancer Center
169. Merck Serono
170. Merck Sharpe & Dohme
171. Mir Lifescience
173. Moderna Therapeutics
174. n3D Biosciences
175. Nanjing Biotech Innovation Corporation
176. Nanjing Legend Biotechnology
178. National Cancer Institute
179. National Resource Center for Mutant Mice
180. National University of Singapore
181. NEOMED Institute
182. New England Discovery Partners
183. Nile Scan & Labs
184. Nimbus Therapeutics
186. NuChem Therapeutics
188. Oncompass Medicine
191. Ontario Institute for Cancer Research
192. Onyx Scientific
194. OriBase Pharma
195. Orion Corporation
198. Oxford Bioscience Partners
199. Oxford University
200. Paraza Pharma
201. Paterson Institute for Cancer Research
205. Pharmaceutical Product Development
206. PharmAgra Labs
210. Piramal Pharma Solutions
211. Prestwick Chemical
213. Provid Pharmaceuticals
214. Queen’s University Belfast
215. Quotient Bioresearch
217. Radboud University
218. Ratnamani Healthcare
219. Reach Separations
220. Red Glead Discovery
221. Redx Pharma
222. Regen BioPharma
224. RTI International
225. Sage Laboratories
226. Sai Life Sciences
227. SAMDI Tech
229. Sapient Discovery
230. SARomics Biostructures
231. SBH Sciences
235. Semmelweis University
236. Shanghai ChemPartner
239. SRI Biosciences
240. Stanford University
241. Sundia MediTech
242. Sygnature Discovery
243. Syncom Healthcare
245. Synvolux Therapeutics
246. Taros Chemicals
247. TATA Group
248. Tata Trusts
249. TC Scientific
250. TCG Lifesciences
251. The Agency for Science, Technology and Research
252. The Eskitis Institute for Drug Discovery
253. The European Molecular Biology Laboratory
254. The Milner Therapeutics Institute
255. The Ohio State University Comprehensive Cancer Center
256. The Rockefeller University
257. The Scripps Research Institute
258. The University Medical Center Groningen
259. The University of Texas MD Anderson Cancer Center
260. The Wellcome Trust Sanger Institute
261. Thermo Fisher Scientific
262. Translational Drug Development
263. Translational Genomics Research Institute
264. Tri-Institutional Therapeutics Discovery Institute
265. Tybema BioSolutions
268. UCB Biopharma
269. United BioPharma
271. University College London
272. University of California, Berkeley
273. University of Cambridge
274. University of Montreal
275. University of Strasbourg
276. University of Tsukuba
277. University of Wisconsin-Madison: School of Pharmacy
278. Vanta Bioscience
279. Vichem Chemie
280. Villapharma Research
282. Viva Biotech
283. Wageningen University
284. Weill Cornell Medicine
285. WIL Research
286. WuXi AppTec
287. York University
288. Zenith Technologies